Navigation Links
Pulmo BioTech Inc. Announces Cash Details of its Previously Announced Letter of Intent Intended to Bring its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) to the European Market
Date:10/24/2009

that PulmoBind(TM) has the potential to dominate the market for the diagnosis of Pulmonary Embolism. In particular, this belief is driven by PulmoScience's expectations of the improved safety and efficacy that PulmoBind(TM) will offer when compared to the current incumbent nuclear medicine based technology for the diagnosis of Pulmonary Embolism. In addition, early indications are that PulmoBind(TM) could be highly effective in the early stage diagnosis of Pulmonary Hypertension, a condition for which there is no current front line diagnostic test. The addressable market for the product candidates being developed by PulmoScience is believed by the company to be worth in excess of $500 million per annum.

About BioTechnology Consulting Poland Sp. z.o.o.

BioTechnology Consulting Poland Sp. z.o.o. is a Polish based company which has been set up to enable the rapid approval of products developed outside the Euro Zone in the European market.

Pursuant to the License Agreement contemplated by the LOI, BioTechnology Consulting Poland will license IP from Pulmo BioTech to enable it to rapidly carry out Phase Trials and ultimately commercialize PulmoBind(TM) across the whole of the European Union and European Economic Area.

BioTechnology Consulting Poland counts amongst its key staff, professionals in the areas of medical project management, new business start-up and growth, and medical Phase Trials. BioTechnolgy Consulting Poland has links with key Polish medical facilities, CROs and Pharmaceutical companies.

Further Information

For further information regarding Pulmo BioTech Inc. or PulmoScience, please visit www.pulmobiotech.com

Forward-Looking Statements

Forward-looking statements contained in this and other written and oral reports are made based on known events and circumstances at the time of release, and as such, are subject in the future to unforeseen uncertainties and risks. Al
'/>"/>

SOURCE Pulmo BioTech Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related biology technology :

1. MAQUET Cardiovascular Announces Leading Robotic Heart Surgeon Performs First Beating Heart Fully Endoscopic Bypass Surgery Using Miniaturized Cardiopulmonary Bypass System
2. InterMune Announces Collaboration With National Jewish Health on NIH-Supported Genetic Research in Idiopathic Pulmonary Fibrosis
3. Actelion Launches Increased Strength Formulation of Ventavis (Iloprost) for Pulmonary Arterial Hypertension in the United States
4. Biomodels Expands Efforts in Cancer Supportive Care, Pulmonary Fibrosis; Preclinical Research Organization Names Dr. Stephen T. Sonis as Partner
5. DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation
6. Oncothyreons PX-866 is effective in preclinical model of pulmonary fibrosis
7. Pulmonary Hypertension Association Names Dr. Nicholas Hill Recipient of 2009 Award of Excellence in Pulmonary Arterial Hypertension (PAH) Care
8. University of Illinois Medical Center in Chicago First Hospital to Install Innovative Shape-HF™ Cardiopulmonary Testing System
9. Pulmo BioTech Inc. Announces Paper to be Presented at Symposium
10. FDA Approves SYMBICORT(R) for Chronic Obstructive Pulmonary Disease (COPD)
11. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... ROCKVILLE, Md. , May 21, 2013 /PRNewswire/ ... "Phase 1 study of margetuximab (MGAH22), an Fc-modified ... solid tumors expressing the HER2 oncoprotein," will be ... American Society of Clinical Oncology during the Developmental ... June 3 at 4:15 – 4:30 PM.  The ...
(Date:5/21/2013)... New York, NY (PRWEB) May 21, 2013 ... years. And according to My Cleaning Products, many turn to ... However, because of the health and environmental risks those solutions ... bugs with Bed Bug Bully instead. , According ... on bed bugs as they used to be. It shared ...
(Date:5/21/2013)... May 21, 2013 Inflamax scientists ... the ITN to design the study, which will ... key clinical models used in the study of ... Nasal Allergen Challenge (NAC) models. Although both the ... publications, to date no direct comparison between the ...
(Date:5/21/2013)... SoundConnect is pleased to announce the release ... in Canada. Lync is the next generation of ... and organizations to collaborate and communicate much more easily ... the United States. With the progressive rollout of Lync ... Canada, SoundConnect now offers a complete Microsoft Lync solution ...
Breaking Biology Technology:MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 2New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 3Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation. 2SoundConnect Announces Microsoft Lync Release in Canada 2SoundConnect Announces Microsoft Lync Release in Canada 3
... 23, 2010 Martek Biosciences, a company that launched ... University of Maryland, entered an agreement on December 21 ... NV for $1.1 billion, the companies jointly announced. ... is the second company sold for more than $1 ...
... Stanford University in the USA has an X-FEL (X-ray Free ... provides images of ,molecules in action, using a kilometer-long electron ... an alternative that can do many of the same things. ... half a million euro. That,s why the researchers have jokingly ...
... Md., Dec. 22, 2010 Novavax, Inc. (Nasdaq: ... Massachusetts Medical School, led by Dr. Trudy Morrison, published ... Virology, a report indicating that a novel virus-like particle ... mice from a live virus challenge.  This vaccine candidate ...
Cached Biology Technology:Martek Is Second Mtech Company Sold for More Than $1 Billion in Three Years 2Martek Is Second Mtech Company Sold for More Than $1 Billion in Three Years 3Martek Is Second Mtech Company Sold for More Than $1 Billion in Three Years 4Eindhoven University builds affordable alternative to mega-laser X-FEL 2Eindhoven University builds affordable alternative to mega-laser X-FEL 3NOVAVAX and University of Massachusetts Medical School Publish Preclinical Safety and Efficacy Study of a Respiratory Syncytial Virus (RSV) Virus-like Particle (VLP) Vaccine Candidate 2NOVAVAX and University of Massachusetts Medical School Publish Preclinical Safety and Efficacy Study of a Respiratory Syncytial Virus (RSV) Virus-like Particle (VLP) Vaccine Candidate 3NOVAVAX and University of Massachusetts Medical School Publish Preclinical Safety and Efficacy Study of a Respiratory Syncytial Virus (RSV) Virus-like Particle (VLP) Vaccine Candidate 4
(Date:5/19/2013)... Davis have engineered a strain of photosynthetic cyanobacteria to ... their findings today at the 113th General Meeting of ... we used synthetic biology approaches to probe and rewire ... for growth) cyanobacterial metabolism for the ability to grow ... on the study. He is part of Shota ...
(Date:5/18/2013)... 2013) Research presented at Digestive Disease Week ... through diet and lifestyle. , Individuals suffering ... muscle strength, fatigue and poor quality of life. ... in remission. A randomized, double blind, placebo-controlled study ... supplementation corresponded to significant relief of these symptoms. ...
(Date:5/17/2013)... provide the white noise of the South, but the night ... Southern air hangs heavy from the humidity and the sounds ... 140 species of frogs, toads and salamanders, is the center ... and swamps are the auditorium for their symphonic choruses, the ... Initiative, or ARMI, have front-row seats. , Amphibians, ...
Breaking Biology News(10 mins):Research examines new methods for managing digestive health 2Research examines new methods for managing digestive health 3Front-row seats to climate change 2Front-row seats to climate change 3Front-row seats to climate change 4
... clinical practice guideline, "Tonsillectomy in Children" will be published ... Surgery (watch for a new cover and publisher ... provides evidence-based recommendations on the pre-, intra-, and postoperative ... years under consideration for tonsillectomy. Additionally, this guideline is ...
... CORVALLIS, Ore. Members of the engineering faculty ... of radiation detection and measurement device that will be ... making the process faster, more accurate and less expensive. ... type of radiation spectrometer, and the first production of ...
... result in long waiting times for seriously ill patients. ... for the next available treatment. In this edition of ... 2010; 107[50]: 892𔃆), Michael Christ and his coauthors ... of emergency patients. Triage provides reliable methods that ...
Cached Biology News:Tonsillectomy in children 2New technology to speed cleanup of nuclear contaminated sites 2